Cyclerion Therapeutics Files 2024 10-K
Ticker: CYCN · Form: 10-K · Filed: Mar 4, 2025 · CIK: 1755237
| Field | Detail |
|---|---|
| Company | Cyclerion Therapeutics, Inc. (CYCN) |
| Form Type | 10-K |
| Filed Date | Mar 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, annual-report
Related Tickers: CYCN
TL;DR
CYCN filed its 2024 10-K. Full financial picture inside.
AI Summary
Cyclerion Therapeutics, Inc. filed its 2024 10-K on March 4, 2025, reporting on its fiscal year ending December 31, 2024. The filing details its business operations, financial condition, and risk factors. Key financial data and operational highlights for the period are presented within the report.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Cyclerion's performance and strategic direction for the past fiscal year, influencing investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Cyclerion faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-04 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Cyclerion Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-04 (date) — Filing date
- 301 BINNEY STREET, CAMBRIDGE, MA 02142 (address) — Company business and mail address
- 617-621-7722 (phone_number) — Company business phone
FAQ
What is the primary business of Cyclerion Therapeutics, Inc. as described in the 10-K?
The filing indicates Cyclerion Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the reported fiscal year end for this 10-K filing?
The conformed period of report is 20241231, meaning the fiscal year ended on December 31, 2024.
When was this 10-K filed with the SEC?
This 10-K was filed on March 4, 2025 (accession number 0000950170-25-032037).
What is the company's principal executive office address?
The company's business and mail address is 301 BINNEY STREET, CAMBRIDGE, MA 02142.
What is the SEC file number for Cyclerion Therapeutics, Inc.?
The SEC file number is 001-38787.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 4, 2025 regarding Cyclerion Therapeutics, Inc. (CYCN).